Langermann Sol's most recent trade in Nextcure Inc was a trade of 117,375 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nextcure Inc | Sol Langermann | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 117,375 | 117,375 | - | - | Employee Stock Option (Right to Buy) | |
| Nextcure Inc | Sol Langermann | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 93,900 | 93,900 | - | - | Employee Stock Option (Right to Buy) | |
| Nextcure Inc | Langermann Sol | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 117,375 | 117,375 | - | - | Employee Stock Option (Right to Buy) | |
| Nextcure Inc | Sol Langermann | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 135,000 | 135,000 | - | - | Employee Stock Option (Right to Buy) | |
| Nextcure Inc | Sol Langermann | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 117,400 | 117,400 | - | - | Employee Stock Option (Right to Buy) | |
| Nextcure Inc | Sol Langermann | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 100,000 | 100,000 | - | - | Employee Stock Option (Right to Buy) |